Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
FY2025 · 10-K disclosure
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 21.07 | Oscillator | Buy |
| Stochastic %K (14, 3, 3) | 18.03 | Oscillator | Buy |
| Williams %R (14) | -72.23 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.04 (Hist -0.01) | Oscillator | Strong Sell |
| Average Directional Index (14) | 36.68 (+DI 7.5 / -DI 31.8) | Trend | Strong Sell |
Current price $0.2346
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Jan 2, 26 |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| May 20, 26 | Trucco Federico | director, officer: CEO | G-Gift | 130,000 | — |
| EMA 20 | 0.30 | MA | Strong Sell |
| SMA 20 | 0.31 | MA | Strong Sell |
| EMA 50 | 0.34 | MA | Strong Sell |
| SMA 50 | 0.37 | MA | Strong Sell |
| SMA 200 | 0.50 | MA | Strong Sell |
| Canaccord Genuity |
| maintain |
| Hold |
| Hold |
| Nov 14, 25 | Canaccord Genuity | maintain | Hold | Hold |
| Sep 10, 25 | Canaccord Genuity | downgrade | Buy | Hold |
| Sep 10, 25 | Lake Street | maintain | Buy | Buy |
| Jul 15, 25 | Oppenheimer | maintain | Outperform | Outperform |
| Apr 22, 25 | Oppenheimer | maintain | Outperform | Outperform |
| Feb 13, 25 | Canaccord Genuity | maintain | Buy | Buy |
| Feb 7, 25 | Lake Street | maintain | Buy | Buy |
| Feb 7, 25 | Canaccord Genuity | maintain | Buy | Buy |
| May 20, 26 |
| Trucco Federico |
| director, officer: CEO |
| G-Gift |
| 150,000 |
| — |
| Aug 3, 26 | Simmermacher Ezequiel | officer: CFO | A-Award | 375,000 @ $1.45 | $543.8K |
| Jun 30, 28 | Duraiswami Narain | director | 150,000 @ $1.50 | $225.0K |
| Jan 5, 26 | Simmermacher Ezequiel | officer | 0 | — |
| Jul 12, 22 | Mago Yogesh | director | 0 | — |
| Mar 13, 19 | Trucco Federico | director, officer: CEO | 0 | — |
| Apr 24, 19 | Trucco Federico | director, officer: CEO | 300,000 @ $4.55 | $1.36M |
Stock news · updated daily
Chemours (NYSE: CC - Get Free Report) and Bioceres Crop Solutions (NASDAQ: BIOX - Get Free Report) are both materials companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk. Risk and Volatility Chemours has a beta of
Rayonier Advanced Materials (NYSE: RYAM - Get Free Report) and Bioceres Crop Solutions (NASDAQ: BIOX - Get Free Report) are both small-cap materials companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, dividends and risk. Insider and Institutional Ownership 68.6%
Bioceres Crop Solutions (NASDAQ: BIOX - Get Free Report) and Neo Performance Materials (OTCMKTS:NOPMF - Get Free Report) are both small-cap materials companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk. Profitability This table compares Bioceres
Bioceres Crop Solutions Corp. (BIOX) Q4 2026 Earnings Call Transcript
ROSARIO, Argentina--(BUSINESS WIRE)--Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ: BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the fiscal fourth quarter ended June 30, 2026. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in t.
ROSARIO, Argentina--(BUSINESS WIRE)--Bioceres Crop Solutions Corp. (NASDAQ: BIOX) (“Bioceres” or the “Company”), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, will hold a conference call on Tuesday, September 15, 2026 at 8:30 a.m. Eastern Time to discuss its results for the fiscal fourth quarter and full year ended June 30, 2026. A press release detailing these resul.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Sep 14, 2026 | -0.06 | -0.39 | Miss -542.0% | $55.90M |
| May 11, 2026 | -0.05 | -0.16 | Miss -220.0% | $39.40M |
| Mar 13, 2026 | 0.07 | -0.08 | Miss -214.3% | $73.67M |
| Nov 13, 2025 | -0.04 | -0.12 | Miss -200.0% | $77.50M |
| Sep 9, 2025 | 0.10 | -0.70 | Miss -800.0% | $74.70M |
| May 21, 2025 | -0.10 | -0.02 | Beat 80.0% | $60.60M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 6-K | Sep 21, 2026 | 2026-09-21 06:09:42 | View |
| 6-K | Sep 16, 2026 | 2026-09-15 19:04:13 | View |
| 4/A | Aug 10, 2026 | 2026-08-10 18:57:36 | View |
| 4 | Aug 6, 2026 | 2026-08-06 11:25:48 | View |
| 4 | Aug 4, 2026 | 2026-08-04 14:44:47 | View |
| SC 13D/A | Jul 7, 2026 | 2026-07-07 19:08:04 | View |
| 6-K | Jun 22, 2026 | 2026-06-22 06:04:01 | View |
| SC 13D/A | Jun 1, 2026 | 2026-06-01 17:16:22 | View |
| 6-K | Jun 1, 2026 | 2026-06-01 10:16:16 | View |
| 3 | May 12, 2026 | 2026-05-12 17:20:03 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | BIOX | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.1x | 34.7x · sector 16.6x | Discount |
| Forward P/E (FY27E) | 4.7x | EPS est. 0.05 | Discount |
| Price / Book | 0.4x | 2.2x | Discount |
| Price / Sales | 0.1x | 1.2x | Discount |
| EV / EBITDA | 90.5x | 494.1x | Discount |
| Return on equity | -216.1% | — | Weak |
| Gross margin | 35.4% | 38.7% | In line |
| Debt / Equity | 6.06 | 2.03 | Levered |
| Piotroski / Altman Z | 3/9 | Z 0.36 | Distress |
Discounted cash flow model